Product Information
VERAPAMIL ER 240 MG TABLET is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $0.1761 per EA under NDC 68462026005. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Sep 17, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
240 mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462026005
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VERAPAMIL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA078906FDA Approved
9/17/2009
TE Code
AB
On Market Since
9/17/2009
Pharmacological Classes
Price Statistics
The NADAC for VERAPAMIL ER 240 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1761 per EA |
|---|---|
| All-time high | $0.2579 (Jan 15, 2014) |
| All-time low | $0.1165 (Dec 19, 2018) |
| 52-week high | $0.1790 |
| 52-week low | $0.1616 |
| Median price | $0.1658 |
| Average price | $0.1678 |
| Largest weekly change | +46.9% (Dec 18, 2013) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
verapamil hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcium Channel Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VERAPAMIL ER 240 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VERAPAMIL ER 240 MG TABLET, manufactured by Glenmark Pharmaceuticals Inc., USA, is $0.1761 per EA (NDC 68462026005), effective Sep 30, 2026.
How has the price of VERAPAMIL ER 240 MG TABLET changed over time?
Over the history we have for it, the NADAC for VERAPAMIL ER 240 MG TABLET has held within roughly two percent of its current level. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for VERAPAMIL ER 240 MG TABLET?
Since Nov 28, 2013, the NADAC for VERAPAMIL ER 240 MG TABLET has ranged from a low of $0.1165 (Dec 19, 2018) to a high of $0.2579 (Jan 15, 2014), with a median of $0.1658 per EA.
Are there cheaper alternatives to VERAPAMIL ER 240 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as VERAPAMIL ER 240 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures VERAPAMIL ER 240 MG TABLET?
VERAPAMIL ER 240 MG TABLET (NDC 68462026005) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.